SIGA (SIGA) Q2 2026 Earnings Call Transcript
SIGA Technologies reported Q2 2026 results in an earnings call. Total revenue fell to $41.0M from $81.1M due to delivery timing. Operating income was $13.9M and net income $12.5M, with diluted EPS $0.17. Cash was $117.6M, zero debt. Management said the final IV TPOXX order under the 19C contract was completed and a new U.S. contract is targeted after slower HHS transitions.
How this was made
The 30-second read
Why it matters
The earnings call combines updated financial results with operational milestones: completion of the final 19C IV TPOXX order, ongoing successor U.S. contract negotiations, and planned FDA submissions for post-exposure prophylaxis and pediatric liquid formulation.
Market read
Traders can update expectations for SIGA’s revenue trajectory based on contract transition timing and the company’s stated regulatory and international delivery targets.
What to watch
The call emphasizes slower progress on the successor U.S. contract due to HHS leadership transitions, but it does not quantify how much backlog or delay will flow into 2026 revenue, leaving a key valuation driver under-specified.
Background
SIGA’s business is tied to government procurement and stockpile replenishment for TPOXX, with quarter-to-quarter variability driven by delivery schedules.
Ticker impact
SIGA reported Q2 2026 revenue of $41.0M and said it completed the final IV TPOXX order under the 19C contract, while negotiating a successor deal.
Choppy-to-soft near term on contract timing risk, with upside sensitivity to any confirmation of successor U.S. contract pace and FDA milestone progress.
The article provides fresh quarterly financials plus specific operational updates: completion of the final 19C order, slower successor-contract progress due to HHS transitions, and targeted FDA submission in 1H 2027. However, it does not disclose contract award terms or new clinical efficacy/regulatory outcomes that would remove key uncertainty.
Market effects
Biodefense and smallpox countermeasure demand remains tied to government stockpile procurement cycles, with execution risk around BARDA-to-SNS transitions.
International sales growth is framed around Middle East and North Africa commercialization via Hikma MENA, plus Europe and Asia-Pacific oral formulation deliveries.
Preparedness procurement and licensing/distribution arrangements can shift revenue timing across regions, affecting biodefense peers’ sentiment even without direct peer-specific news.
Counterpoint
The quarter’s revenue and earnings decline may be largely timing-related, and the company’s cash position and zero-debt balance sheet could reduce downside risk versus the income statement.
Key entities
- companySIGA Technologies, Inc.
Reported Q2 2026 financial results and provided updates on TPOXX deliveries, successor U.S. contract negotiations, and upcoming FDA-related milestones.
- personDiem Nguyen
CEO who attributed successor-contract delays to HHS leadership transitions and priority shifts.
- personDaniel Luckshire
CFO who discussed financial performance and balance sheet details including zero debt and cash levels.
- companyHikma MENA FZE
Named as the exclusive license and distribution partner for TPOXX commercialization across Middle East and North Africa.
